Register for our free email digests:
Latest From Moebius Medical Ltd.
Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Biogen Idec Hemophilia Inc.
- Syntonix Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- Bioverativ Inc.
- Senior Management
John G Cox, CEO
John Greene, EVP, CFO
Tim Harris, PhD, DSc, EVP, R&D
Richard Brudnick, EVP, Bus. Dev. & Alliance Management
- Contact Info
Phone: (781) 663-4400
225 Second Ave.
Waltham, MA 02451
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.